Equillium Stock Price, News & Analysis

Equillium (Nasdaq: EQ) presented new data on its lead drug, itolizumab, at the IMMUNOLOGY2022 conference. The findings suggest that itolizumab effectively reduces CD6 levels on T effector cells, promoting the development of T regulatory cells, which could enhance treatment strategies for autoimmune diseases. The data indicates that targeting the CD6-ALCAM pathway can prevent harmful T cell recruitment into inflamed organs. Currently in Phase 3 trials for acute graft-versus-host disease, itolizumab shows promise for addressing significant unmet medical needs in immunology.

Equillium, Inc. presented promising data on itolizumab for treating acute graft-versus-host disease (aGVHD) at the Transplantation & Cellular Meetings. The findings indicate a 52% complete response rate and a 64% overall response at Day 29, with ongoing responses observed over 12 months. The data suggests 73% of responders were able to taper corticosteroids significantly. The study also emphasizes the importance of achieving high serum concentrations of itolizumab early on for maximum efficacy, supporting its progression into a pivotal Phase 3 trial.

Equillium, Inc. (Nasdaq: EQ) announced a presentation at the Italian Society of Experimental Hematology Congress, showcasing data on its monoclonal antibody, itolizumab. The study, involving 95 adult patients treated at Dana-Farber Cancer Institute, highlights itolizumab's effectiveness in inhibiting pathogenic T cell proliferation in acute graft-versus-host disease (aGVHD). The findings support advancing itolizumab into a Phase 3 study for first-line aGVHD treatment. This innovative therapy targets the CD6-ALCAM pathway, vital for T cell modulation.

Equillium, Inc. (Nasdaq: EQ) announced positive topline data from the EQUATE study of itolizumab for acute graft-versus-host disease (aGVHD) and initiated the EQUATOR Phase 3 study. The company also presented interim safety data showing a reduction in proteinuria in lupus patients from the EQUALISE study. Additionally, Equillium acquired Bioniz Therapeutics, enhancing its pipeline with two clinical-stage assets. For 2021, R&D expenses rose to $26.4 million, while the net loss was $39.1 million, which is an increase from $29.8 million in 2020. Cash and equivalents stood at $80.7 million.

Equillium, Inc. (NASDAQ: EQ) presented promising results from its EQUATE study on itolizumab for treating high-risk acute graft-versus-host disease (aGVHD) at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation. Key findings include a 72% overall survival rate at 12 months and significant progression-free survival. At Day 29, 52% of patients achieved a complete response (CR), with 64% overall response rate (ORR). Remarkably, responders reduced corticosteroid use by 73% at Day 29 and 96% at six months, suggesting itolizumab's potential as an effective first-line therapy.

Equillium has initiated the EQUATOR study, a pivotal Phase 3 clinical trial assessing itolizumab as a first-line treatment for acute graft-versus-host disease (aGVHD). The study aims to enroll up to 200 patients globally, with primary endpoints focusing on complete response at Day 29. The previous EQUATE study demonstrated promising results, with a complete response rate of 52% in high-risk patients. Equillium has also received fast track and orphan drug designations from the FDA for itolizumab.

Equillium, Inc. (Nasdaq: EQ) has appointed Dr. Barbara Troupin to its Board of Directors, where she will serve on the Nominating and Corporate Governance Committee. Dr. Troupin brings extensive experience in clinical development and regulatory affairs, crucial as Equillium prepares for its Phase 3 study for acute graft-versus-host disease. Her previous roles include senior vice president at Myokardia and chief medical officer positions at ERX Pharmaceuticals, Aquinox, and Apricus Biosciences. This leadership addition may enhance Equillium's capabilities in novel therapeutics targeting severe autoimmune disorders.

Equillium has acquired Bioniz Therapeutics, enhancing its immunology pipeline with two first-in-class clinical assets and a proprietary discovery platform. The acquisition, valued at 5,699,492 shares of common stock (approximately 19.3% of Equillium’s capital), aims to drive significant growth through advanced therapeutic candidates for autoimmune and inflammatory diseases. Key products include BNZ-1, progressing to Phase 2 trials for alopecia areata, and BNZ-2, set to enter Phase 1 for celiac disease. Equillium retains exclusive rights to all Bioniz products, reinforcing its strategic position in the market.

Equillium, Inc. (NASDAQ: EQ), a clinical-stage biotechnology company, announced updates for its conference participation. The company will hold a virtual fireside chat at the SVB Leerink Virtual Global Healthcare Conference on February 17, 2022, at 2:20 pm ET, with a live webcast available on its website. Additionally, the dates for the American Society of Transplantation and Cellular Therapy conference have been rescheduled to April 23-26, 2022, and will be held both virtually and in-person in Salt Lake City. Equillium is focused on developing itolizumab for severe autoimmune and inflammatory disorders.